Jump to content

Netupitant/palonosetron

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by 62.192.250.172 (talk) at 23:11, 23 April 2015. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Netupitant/palonosetron
Combination of
NetupitantNK1 receptor antagonist
Palonosetron5-HT3 receptor antagonist
Clinical data
Trade namesAkynzeo

Netupitant/palonosetron (Akynzeo) is a fixed dose combination drug for prevention of acute and delayed nausea and vomiting associated with cancer chemotherapy.[1] Netupitant is an NK1 receptor antagonist and palonosetron is a 5-HT3 receptor antagonist.

References

  1. ^ "FDA approves Akynzeo for nausea and vomiting associated with cancer chemotherapy". Food and Drug Administration. October 10, 2014.
Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Netupitant/palonosetron&oldid=658911281"